HDAC inhibitors as anti-inflammatory agents

Area of Science:

• Biochemistry and Molecular Biology
• Cellular Regulation
• Epigenetics

Background:

• Cellular functions like inflammatory gene expression, DNA repair, and proliferation are modulated by histone and non-histone protein acetylation.
• Aberrant histone acetylation patterns are linked to various human diseases, notably cancer.
• Histone acetyltransferases (HATs), acting as transcriptional co-activators, show abnormal expression and activation in inflammatory diseases.

Discussion:

• Histone deacetylase (HDAC) inhibitors are clinically utilized for malignancies due to their impact on apoptosis.
• Emerging evidence suggests HDAC inhibitors possess anti-inflammatory properties by inducing cell death through non-histone protein acetylation.
• While long-term safety concerns exist, HDAC inhibitors may offer therapeutic benefits in cases with suboptimal anti-inflammatory treatments.

Key Insights:

• Acetylation status of histones and non-histone proteins is crucial for regulating fundamental cellular processes.
• HDAC inhibitors, initially developed for cancer, demonstrate a novel anti-inflammatory mechanism via non-histone protein acetylation and cell death.
• The therapeutic potential of HDAC inhibitors extends beyond oncology to inflammatory conditions.

Outlook:

• Further research is warranted to fully elucidate the anti-inflammatory mechanisms of HDAC inhibitors.
• Clinical investigation into the efficacy and safety of HDAC inhibitors for inflammatory diseases is a promising future direction.
• HDAC inhibitors could represent a valuable therapeutic option for patients with inflammatory conditions unresponsive to current therapies.